Group 1 - Ikena Oncology, Inc. (IMA) shares have increased by 2.4% over the past four weeks, closing at $16.6, with a mean price target of $132.05 indicating a potential upside of 695.5% [1][2] - The mean estimate includes three short-term price targets with a standard deviation of $125.33, where the lowest estimate suggests an increase of 189.3% and the highest indicates a surge of 1563.3% to $276.11 [2] - Analysts show strong agreement on IMA's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for IMA has increased by 51.5% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - IMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Group 1 - Forge Global Holdings, Inc. (FRGE) closed at $23, with a 26.8% gain over the past four weeks, and has a mean price target of $33.6, indicating a 46.1% upside potential [1] - The average price targets range from a low of $18.00 to a high of $60.00, with a standard deviation of $15.65, suggesting variability in analyst estimates [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.8% over the past month, with two estimates going higher and no negative revisions [12] - FRGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement [14]

Group 1 - Precision Drilling (PDS) closed at $53.58, with a 7.9% gain over the past four weeks, and a mean price target of $70.3 indicating a 31.2% upside potential [1] - The average price targets from analysts range from a low of $51.70 to a high of $87.60, with a standard deviation of $10.04, suggesting variability in estimates [2] - Analysts show strong agreement on PDS's ability to report better earnings, with a positive trend in earnings estimate revisions indicating potential upside [4][11] Group 2 - The Zacks Consensus Estimate for PDS has increased by 20.8% over the past month, with no negative revisions, reflecting growing optimism about the company's earnings prospects [12] - PDS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Core Viewpoint - EZcorp (EZPW) shows potential for significant upside, with a mean price target of $21 indicating a 42.5% increase from its current price of $14.74 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $3.37, suggesting variability among analysts [2] - The lowest estimate is $17.00, indicating a 15.3% increase, while the highest estimate is $25.00, suggesting a 69.6% increase [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about EZPW's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, one estimate has increased, leading to a 2.9% rise in the Zacks Consensus Estimate [12] - EZPW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]

Core Viewpoint - Udemy, Inc. (UDMY) shows potential for upside with a mean price target of $9.75, indicating a 34.1% upside from its current price of $7.27 [1] Price Targets and Analyst Consensus - The average price target consists of 10 estimates ranging from $6.50 to $12.00, with a standard deviation of $1.65, suggesting variability in analyst predictions [2] - The lowest estimate indicates a potential decline of 10.6%, while the highest suggests a 65.1% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about UDMY's earnings, with a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 17.7%, with two estimates moving higher and no negative revisions [12] - UDMY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, and reliance solely on them may lead to poor investment decisions [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Group 1 - Vermilion Energy (VET) shares have increased by 5.9% over the past four weeks, closing at $7.95, with a mean price target of $10 indicating a potential upside of 25.8% [1] - The average price targets from analysts range from a low of $7.56 to a high of $12.52, with a standard deviation of $1.57, suggesting variability in estimates [2] - Analysts have shown strong agreement in revising VET's earnings estimates higher, which correlates with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for VET's current year earnings has increased by 152.2% over the last 30 days, indicating positive sentiment among analysts [12] - VET holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of VET's gains, they can provide guidance on the direction of price movement [14]

Group 1 - The stock of Omnicell (OMCL) closed at $31.01, showing a 3.9% increase over the past four weeks, with a mean price target of $44.8 indicating a potential upside of 44.5% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $9.73, where the lowest estimate is $34.00 (9.6% increase) and the highest is $57.00 (83.8% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.9%, with one estimate moving higher and no negative revisions [12] - OMCL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does suggest a positive direction for price movement [14]

Group 1 - Beyond (BYON) shares have increased by 18.9% over the past four weeks, closing at $8.95, with a mean price target of $14.08 indicating a potential upside of 57.3% [1] - The average price targets range from a low of $5.00 to a high of $36.00, with a standard deviation of $11.06, suggesting variability in analyst estimates [2] - Analysts have shown a strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for BYON's current year earnings has risen by 17.5% over the past month, with two estimates increasing and no negative revisions [12] - BYON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Dyne Therapeutics, Inc. (DYN) shows significant upside potential with a mean price target of $38.21, indicating a 285.6% increase from the current trading price of $9.91 [1] Price Targets and Estimates - The mean estimate consists of 17 short-term price targets with a standard deviation of $14.79, suggesting variability in analyst predictions. The lowest estimate is $9.00 (9.2% decline), while the highest is $66.00 (566% increase) [2] - Analysts' price targets can be misleading, as empirical research indicates they rarely accurately predict stock price movements [7][10] Earnings Estimates - Analysts have shown increasing optimism regarding DYN's earnings, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 6.1%, with four estimates moving higher and no negative revisions [12] Analyst Rankings - DYN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable measure of DYN's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Genius Sports Limited (GENI) has shown a 0.7% increase in share price over the past four weeks, closing at $10.17, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $12.82, representing a 26.1% upside [1] Price Targets - The average of 17 short-term price targets ranges from a low of $11.00 to a high of $15.00, with a standard deviation of $1.13, indicating variability among analysts [2] - The lowest estimate suggests an 8.2% increase from the current price, while the highest estimate indicates a 47.5% upside [2] Analyst Sentiment - Analysts have shown increasing optimism regarding GENI's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 6.2% over the past month, with one estimate increasing and no negative revisions [12] Zacks Rank - GENI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the extent of potential gains for GENI, it does provide a useful guide for the direction of price movement [14]